The Value of Gadobenate Dimeglumine-Enhanced Delayed Phase MR Imaging for Characterization of Hepatocellular Nodules in the Cirrhotic Liver

Objectives:To evaluate the value of 1-hour delayed phase imaging (DPI) of gadobenate dimeglumine (Gd-BOPTA)-enhanced MR imaging for the characterization of hepatocellular carcinoma (HCC) and dysplastic nodule (DN) in patients with cirrhosis. Materials and Methods:A total of 37 patients with 42 HCCs and 13 DNs were included in this study and all lesions were histopathologically confirmed except for 15 HCCs. T1-weighted 3-dimensional gradient-echo images were acquired before, immediately after (30, 60, 180 s), and 1 hour after bolus injection of gadobenate dimeglumine at a dose of 0.1 mmol/kg. The lesions were classified as isointense, hypointense, or hyperintense compared with the surrounding liver parenchyma on DPI for qualitative assessment. We performed quantitative analyses of the contrast-to-noise ratio (CNR) and of the relative contrast enhancement of the lesion on the DPI. Results:In the qualitative analysis, among 42 HCCs, 30 (71.4%) were hypointense on DPI, and 10 (23.8%) and 2 (4.8%) were isointense and hyperintense, respectively; only 1 of 13 DNs (7.7%) was hypointense and 10 (76.9%) and 2 (15.4%) were isointense and hyperintense, respectively. In contrast, 25 HCCs (71.4%) of 35 hypervascular HCCs were hypointense on DPI, and no hypervascular DN (0/7) was hypointense with statistical significance (P = 0.0007). When we considered the hypointensity of the hepatic lesions on delayed phase as a sign of HCC in cirrhotic liver, our results gave a sensitivity of 71.4% and a specificity of 91.7%. In the quantitative analysis, the mean CNR of the HCCs and the DNs on the 1-hour DPI was −6.32 ± 6.27 and −0.07 ± 3.28, respectively; the difference between the HCCs and the DNs was significant (P < 0.05). Conclusions:Delayed gadobenate dimeglumine-enhanced MR imaging allows improved characterization of HCC in cirrhotic liver. The relative hypointensity to adjacent normal liver parenchyma is a reliable predictor that this lesion favors HCC rather than DN in cirrhotic liver.

[1]  O. Matsui,et al.  Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. , 1991, Radiology.

[2]  C. Becker,et al.  Model-Based Analysis of Gd-BOPTA-Induced MR Signal Intensity Changes in Cirrhotic Rat Livers , 2007, Investigative radiology.

[3]  H. Hussain,et al.  T2-weighted MR imaging in the assessment of cirrhotic liver. , 2004, Radiology.

[4]  G. Morana,et al.  Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. , 2000, Investigative radiology.

[5]  T. Murakami,et al.  Superparamagnetic iron oxide–enhanced magnetic resonance images of hepatocellular carcinoma: Correlation with histological grading , 2000, Hepatology.

[6]  P. Mergo,et al.  Characterization of focal hepatic lesions with ferumoxides-enhanced T2-weighted MR imaging. , 2000, AJR. American journal of roentgenology.

[7]  V. Vilgrain,et al.  Small Nodule Detection in Cirrhotic Livers: Evaluation with US, Spiral CT, and MRI and Correlation with Pathologic Examination of Explanted Liver , 2001, Journal of computer assisted tomography.

[8]  G. Marchal,et al.  Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study. , 2000, Radiology.

[9]  E. Hecht,et al.  Hepatocellular carcinoma in the cirrhotic liver: gadolinium-enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis. , 2006, Radiology.

[10]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[11]  G. Schuhmann-Giampieri.  Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging. , 1993, Investigative radiology.

[12]  G. Morana,et al.  Hypervascular hepatic lesions: dynamic and late enhancement pattern with Gd-BOPTA. , 2002, Academic radiology.

[13]  G. Morana,et al.  Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)--preliminary results of phase II clinical application. , 1996, Radiology.

[14]  E. Rummeny,et al.  Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. , 2000, AJR. American journal of roentgenology.

[15]  Young Kon Kim,et al.  Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. , 2006, Radiology.

[16]  V. Lorusso,et al.  Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. , 1999, Academic radiology.

[17]  H. Edmondson,et al.  Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies , 1954, Cancer.

[18]  E. Rummeny,et al.  Low-Dose Gadobenate Dimeglumine Versus Standard Dose Gadopentetate Dimeglumine for Contrast-Enhanced Magnetic Resonance Imaging of the Liver: An Intra-Individual Crossover Comparison , 2003, Investigative radiology.

[19]  P. Robinson,et al.  Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. , 2000, Radiology.

[20]  A. Spinazzi,et al.  Gadobenate dimeglumine (Gd-BOPTA). An overview. , 1998, Investigative radiology.

[21]  Y. Yamashita,et al.  Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium- and ferumoxides-enhanced MR imaging. , 1999, AJR. American journal of roentgenology.

[22]  P. Taroni,et al.  Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. , 1998, Academic radiology.

[23]  T. Murakami,et al.  Hepatic malignancies: usefulness of acquisition of multiple arterial and portal venous phase images at dynamic gadolinium-enhanced MR imaging. , 1996, Radiology.

[24]  G. Morana,et al.  Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. , 2005, Radiology.

[25]  Young Kon Kim,et al.  Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions , 2004, European Radiology.

[26]  R. Weissleder,et al.  MR imaging of the liver with Gd‐BOPTA: Quantitative analysis of T1‐weighted images at two different doses , 1999, Journal of magnetic resonance imaging : JMRI.

[27]  N. Rofsky,et al.  Dysplastic nodules and hepatocellular carcinoma: thin-section MR imaging of explanted cirrhotic livers with pathologic correlation. , 1996, Radiology.

[28]  O. Matsui,et al.  Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. , 1999, AJR. American journal of roentgenology.

[29]  Contrast enhancement of small hepatocellular carcinoma: usefulness of three successive early image acquisitions during multiphase dynamic MR imaging. , 1999, AJR. American journal of roentgenology.

[30]  S. Hirohashi,et al.  Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. , 1991, Human pathology.

[31]  N M Rofsky,et al.  Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. , 2001, Radiology.

[32]  K. Ohtomo,et al.  Comparison of Gadobenate Dimeglumine with Gadopentetate Dimeglumine for Magnetic Resonance Imaging of Liver Tumors , 2001, Investigative radiology.

[33]  S. Saini,et al.  Evaluation of a Novel Time-Efficient Protocol for Gadobenate Dimeglumine (Gd-BOPTA)-Enhanced Liver Magnetic Resonance Imaging , 2007, Investigative radiology.

[34]  R. Manfredi,et al.  Gadobenate dimeglumine (BOPTA) enhanced MR imaging: Patterns of enhancement in normal liver and cirrhosis , 1998, Journal of magnetic resonance imaging : JMRI.

[35]  R. Manfredi,et al.  Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd‐BOPTA) , 1999, Journal of magnetic resonance imaging : JMRI.

[36]  W. Pegios,et al.  Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation. , 1997, Radiology.

[37]  P. Bachellier,et al.  Small hepatocellular carcinoma in Child A cirrhotic patients: Hepatic resection versus transplantation , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[38]  J. Figueras,et al.  Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. , 2000, Journal of the American College of Surgeons.

[39]  P. Soyer,et al.  Detection of focal hepatic lesions with MR imaging: prospective comparison of T2-weighted fast spin-echo with and without fat suppression, T2-weighted breath-hold fast spin-echo, and gadolinium chelate-enhanced 3D gradient-recalled imaging. , 1996, AJR. American journal of roentgenology.